Fox Run Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,896
| Closed | -$355K | – | 1021 |
|
|
2025
Q4 | $355K | Sell |
2,896
-9,363
| -76% | -$1.14M | 0.05% | 640 |
|
|
2025
Q3 | $1.36M | Buy |
+12,259
| New | +$1.39M | 0.21% | 117 |
|
|
2025
Q2 | – | Sell |
-5,995
| Closed | -$672K | – | 996 |
|
|
2025
Q1 | $672K | Buy |
5,995
+319
| +6% | +$32.9K | 0.1% | 353 |
|
|
2024
Q4 | $524K | Buy |
+5,676
| New | +$511K | 0.1% | 424 |
|
|
2024
Q2 | – | Sell |
-7,000
| Closed | -$513K | – | 875 |
|
|
2024
Q1 | $513K | Buy |
+7,000
| New | +$538K | 0.11% | 361 |
|
|
2022
Q4 | – | Sell |
-10,283
| Closed | -$634K | – | 726 |
|
|
2022
Q3 | $634K | Buy |
+10,283
| New | +$648K | 0.25% | 103 |
|
|
2022
Q2 | – | Sell |
-9,562
| Closed | -$568K | – | 611 |
|
|
2022
Q1 | $568K | Buy |
9,562
+4,111
| +75% | +$263K | 0.32% | 70 |
|
|
2021
Q4 | $396K | Buy |
+5,451
| New | +$375K | 0.23% | 140 |
|
|
2021
Q3 | – | Sell |
-6,628
| Closed | -$456K | – | 530 |
|
|
2021
Q2 | $456K | Buy |
6,628
+3,193
| +93% | +$213K | 0.41% | 64 |
|
|
2021
Q1 | $222K | Buy |
+3,435
| New | +$221K | 0.4% | 150 |
|
|
2020
Q2 | – | Sell |
-4,250
| Closed | -$318K | – | 281 |
|
|
2020
Q1 | $318K | Sell |
4,250
-3,037
| -42% | -$210K | 0.75% | 22 |
|
|
2019
Q4 | $474K | Buy |
+7,287
| New | +$475K | 0.38% | 51 |
|
|
2019
Q3 | – | Sell |
-3,530
| Closed | -$238K | – | 442 |
|
|
2019
Q2 | $238K | Sell |
3,530
-1,543
| -30% | -$102K | 0.16% | 311 |
|
|
2019
Q1 | $330K | Sell |
5,073
-5,417
| -52% | -$360K | 0.19% | 239 |
|
|
2018
Q4 | $656K | Buy |
10,490
+5,824
| +125% | +$407K | 0.35% | 48 |
|
|
2018
Q3 | $360K | Buy |
+4,666
| New | +$352K | 0.16% | 291 |
|
|
2018
Q1 | – | Sell |
-17,343
| Closed | -$1.24M | – | 790 |
|
|
2017
Q4 | $1.24M | Buy |
+17,343
| New | +$1.32M | 0.36% | 33 |
|
|
2017
Q3 | – | Sell |
-10,700
| Closed | -$757K | – | 742 |
|
|
2017
Q2 | $757K | Buy |
+10,700
| New | +$712K | 0.26% | 104 |
|
|
2017
Q1 | – | Sell |
-14,300
| Closed | -$1.02M | – | 638 |
|
|
2016
Q4 | $1.02M | Buy |
+14,300
| New | +$1.06M | 0.54% | 7 |
|
|
2016
Q3 | – | Sell |
-3,800
| Closed | -$317K | – | 558 |
|
|
2016
Q2 | $317K | Buy |
+3,800
| New | +$337K | 0.15% | 269 |
|
|
2016
Q1 | – | Sell |
-8,700
| Closed | -$880K | – | 465 |
|
|
2015
Q4 | $880K | Buy |
+8,700
| New | +$905K | 0.68% | 6 |
|
Other funds holding GILD
Fox Run Management's GILD Position: Q1 2026 in Review
Fox Run Management sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 2,896 shares — an estimated $355K sold.
Fox Run Management first reported a position in GILD in Q4 2015 and held it in 21 quarters. The position peaked at $1.36M in Q3 2025. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Fox Run Management reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
- Fox Run Management sold 2,896 Gilead Sciences shares in Q1 2026, an estimated $355K.
- Fox Run Management first reported a position in Gilead Sciences in Q4 2015 and held it in 21 quarters.
- Fox Run Management's Gilead Sciences position peaked at $1.36M in Q3 2025.
- 2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.